Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders

Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]

#KDNC Cadence Minerals – Director Share Purchases

Cadence (AIM:KDNC), the mining investment company, announces that on the 8 April the following director purchased ordinary shares in the Company. Director Position Number of ordinary shares acquired Price paid per share (£) Kiran Morzaria Director & CEO 54,422 0.1837 After this acquisition and the transfer of the Employee Benefit Trust (“EBT”) shares under the […]

#TYM Tertiary Minerals – Total Voting Rights

Tertiary Minerals plc (LON: TYM), announces that in accordance with Financial Conduct Authority’s Disclosure and Transparency Rules (“DTRs”), the total issued share capital of the Company with voting rights is 1,536,263,621 ordinary shares. There are no shares currently held in treasury. The total number of voting rights in the Company is therefore 1,536,263,621 and this figure may be used […]

#TYM Tertiary Minerals – Full Exercise of Broker Option

Tertiary Minerals plc (AIM: TYM), the London listed explorer focussed on energy transition and precious metals in Nevada and Zambia, is pleased to announce that, further to the Company’s announcement of a fundraising on 19 January 2022 (the “Fundraising”), the Broker Option, a facility to allow existing shareholders to participate in the Fundraising on similar […]

VectorVest’s David Paul: Finding the Best Shares for a Worry Free Portfolio via Core Finance TV

Core Finance is part of Core London, a TV production company based in Belgravia, London. Core Finance aims to provide its viewers with insightful market commentary, helping investors navigate global financial markets. Making the content provided invaluable to viewers. Our shows are closely followed by fund managers, day traders, retail investors, company CEO’s, experienced investors […]

Advanced Oncotherapy (AVO) – Exercise of warrants and options and issue of shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has agreed to issue 7,166,667 new ordinary shares  of 1p in the Company to Dr. Nick Plowman, Chairman of the Medical Advisory Board, pursuant to the exercise of warrants and options at prices between 1.1 pence and 5 pence. […]

Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 34,122,682 new ordinary shares of 1p in the Company at a price of 1.1 pence per New Share pursuant to the exercise of warrants by Brahma AG. The warrants were issued on 25 September 2013 to […]

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares

Exercise of Warrants and Issue of Shares. Issue of Shares Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 600,000 new ordinary shares of 1p in the Company at a subscription price of 8 pence per Ordinary Share to Dr Enrico Vanni, a non-executive director, […]